As the culture of treating pets like family, known as 'Pet Humanization,' continues to grow, the market for related treatments is also expanding. The global market for canine atopic dermatitis treatments is projected to grow from approximately $2.7 billion in 2025 to $8.2 billion by 2034.
On June 1, HK Inno.N announced that it has completed Phase 3 clinical trials for its oral medication, IN-115314, designed to treat atopic dermatitis in dogs, and has submitted an application for product approval.
IN-115314 is a low-molecular-weight drug developed in-house by HK Inno.N and is the only Janus kinase-1 (JAK-1) inhibitor treatment available in South Korea. Currently, the only other JAK inhibitor for pets on the market is a product containing oclacitinib from a global pharmaceutical company.
The study involved dogs with atopic dermatitis and was conducted at 13 veterinary hospitals across South Korea. It compared the effects of IN-115314 with existing JAK inhibitor treatments, evaluating itchiness, skin lesion improvement, and safety.
The trial was divided into three groups, with one group receiving the control drug twice daily for 28 days, while the other groups received IN-115314 either once daily or twice daily.
Results showed that IN-115314 was effective with just once-daily dosing, achieving results comparable to the competing drug. The average itchiness score decreased from 7.46 at the start of treatment to 2.12 by week four, with the difference in reduction compared to the competing drug ranging from -2.257 to -0.302 points. The improvement in skin lesions also showed significant progress, dropping from an average score of 33.80 to 16.18 by week four.
Notably, IN-115314 demonstrated a rapid initial response with long-lasting effects on itch relief, which could enhance convenience for pet owners and improve treatment satisfaction, especially given the high recurrence rate and ongoing management needs of the condition.
In terms of safety, key physiological indicators such as weight, heart rate, respiratory rate, and temperature remained stable, and no serious adverse reactions related to the trial drug were observed.
The company is also developing a human treatment for atopic dermatitis (in ointment form) based on IN-115314, which is currently undergoing Phase 2 clinical trials in South Korea. Recently, it received approval from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for a Phase 1b trial in the United States.
A representative from HK Inno.N stated, "We plan to expand indications utilizing the JAK inhibitor mechanism for autoimmune skin diseases in the future."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.